Zomagen Biosciences Receives FDA Orphan Designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Zomagen Biosciences Ltd, a wholly owned subsidiary of Ventyx Biosciences, received FDA orphan designation for a treatment of pericarditis, according to a post to the agency's website.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
